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Endothelial Cells of the Human 
Micro vasculature Express Epidermal Fatty 
Acid-Binding Protein
Isabelle Masouye, Gerry Hagens, Toin H. Van Kuppevelt, Peder Madsen, Jean-Hilaire Saurat,
Jacques H. Veerkamp, Michael S. Pepper, Georges Siegenthaler
Abstract Epidermal fatty acid-binding protein (E-FABP), 
previously characterized in human keratinocytes, is a cytoplas­
mic protein of 15 kD that specifically binds fatty acids (FAs), 
Previous PAGE-immunoblotting studies indicated that several 
human tissues display an immunoreactive band with an elec­
trophoretic mobility identical to that of E-FABP. The aim of 
this study was to determine in which cells, other than kerati­
nocytes, E-FABP might be expressed- By immunohis to chemis­
try, we show that E-FABP is expressed in endothelial cells of 
the microvasculature of the placenta, heart, skeletal muscle, 
small intestine, lung, and renal medulla. Interestingly, in lung, 
a tissue of endodermal origin, E-FABP staining was also
The FABPs constitute a superfamily of highly conserved 14- to 15-kD cytosolic lipid-binding proteins. These specific carriers are widely dis­tributed among different cell types and are involved in 
the transport of long chain FAs. Several observations 
suggest that the major function of FABPs is to regulate 
intracellular levels of FAs and their targeting to specific 
metabolic pathways.1-3 FAs are important molecules for 
membrane formation, energy delivery, and lipid media­
tion. It has recently been suggested that FABPs may also 
interact with several FA-mediated cellular processes, 
such as control of cell growth, cell signaling, and regu­
lation of gene transcription (reviewed in References 2, 4,
5, and 6). At least eight FABP types can be discrimi­
nated and have been named after the first tissue in which 
they were identified.1-3 Each FABP type displays a 
characteristic pattern of tissue expression and distinct 
ligand-binding properties, suggesting specific and com­
plementary functions for each protein.
We previously characterized E-FABP in human epi­
dermis and showed that it specifically binds FAs, with 
high affinity for stearic and linoleic acids.7>s Immunohis- 
tological studies revealed that E-FABP is expressed 
during keratinocyte differentiation in human oral mu­
cosa, in human epidermis both under normal and patho-
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localized to secretory cells, ie, Clara cells, goblet cells, and 
probably a subpopulation of pneumocytes. RNA isolated from 
cultured human umbilical vein and normal human dermal 
microvascular endothelial cells was analyzed by reverse-tran- 
scriptase polymerase chain reaction (RT-PCR). Southern blot­
ting and sequencing of the cloned RT-PCR products demon­
strate that endothelial E-FABP is identical to keratinocyte 
E-FABP. These data suggest that E-FABP-mediated FA trans­
port occurs at the level of the microvasculature in several FA  
target organs. (Circ Res. 1997;81:297-303.)
Key Words •  fatty acid • blood vessel •  heart 
• placenta • lung
logical conditions, and in cultured keratinocytes.8,9 
PAGE-autoradioblotting and PAGE-immunoblotting 
studies of various human tissues revealed that E-FABP 
expression is not restricted to keratinocytes, since heart, 
intestine, and adipose tissue showed an immunore active 
band with an electrophoretic mobility identical to that of 
E-FABP from keratinocytes.7’8 To date, the cellular 
localization of E-FABP in nonepithelial tissues is un­
known. Furthermore, it has not been established 
whether E-FABP from keratinocytes is identical to the 
immunoreactive band detected in other tissues.
In the present study, we show that E-FABP is ex­
pressed in nonciliated cells of the bronchial epithelium 
and in endothelial cells of the microvasculature of 
several tissues. By molecular cloning, we show that 
endothelial E-FABP is identical to keratinocyte 
E-FABP. The possible role of E-FABP in blood capillary 
function is discussed.
Materials and Methods 
Tissue Specimens
Specimens from human heart, small intestine, skeletal mus­
cle (quadriceps), lung, and kidney were obtained from autop­
sies (Department of Pathology, University Hospital, Geneva, 
Switzerland) and from biopsies obtained during surgery. Pla­
centa and umbilical cord specimens were obtained immediately 
after obstetrical delivery.
Immunohistochemistry
Tissue samples were fixed for at least 24 hours in 10% 
formalin or Duboscq-Brazil solution and processed for routine 
histology. None of the tissues showed obvious pathological 
alterations by conventional hematoxylin-eosin staining. Rabbit 
antiserum against human E-FABP purified from psoriatic 
scales was obtained as described previously.8 The antiserum 
was specific, since for various tissues, SDS-PAGE and PAGE-
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Selected Abbreviations and Acronyms
DMVEC = human dermal microvascular endothelial cell 
E-FABP = epidermal FABP 
FA = fatty acid 
FABP = FA-binding protein 
H-FABP = heart FABP 
L-FABP = liver FABP 
PA-FABP = psoriasis-associated FABP 
PCR = polymerase chain reaction 
RT-PCR — reverse-transcriptase PCR 
UEA1 = Ulex europaeus agglutinin 1 
vWF = von Willebrand factor
immunoblotting analysis showed only one immunoreactive 
band at 15 kD and Rf (relative mobility) 0.32, respectively.8
Paraffin sections (5 /Am) were permeabilized in 0.3% Triton 
X-100 solution and preincubated with normal goat serum to 
block nonspecific binding sites. After incubation for 60 minutes 
at room temperature with the anti-E-FABP antiserum (dilu­
tion, 1:200), an immunoperoxidase technique using a biotiny- 
lated goat anti-rabbit IgG as secondary antibody and a perox­
idase-conjugated avidin-biotin complex was applied according 
to the manufacturer’s instructions (Vectastain reagents, Vector 
Laboratory). Peroxidase reactivity was then revealed using 
hydrogen peroxide and diaminobenzidine as a chromogenic 
substrate. The sections were lightly counterstained with hema­
toxylin. As a control, preimmune serum from the immunized 
rabbit was used simultaneously on adjacent sections.
We performed comparative stainings on adjacent sections 
using vWF and UEA1 as endothelial markers, together with a 
standard immunoperoxidase technique, vWF was detected 
using a rabbit antiserum directed against human vWF (factor 
VUI-related antigen, Dakopatts). Biotinylated swine anti-rab­
bit immunoglobulins (E353, Dako A/S) and a peroxidase- 
conjugated streptavidin-biotin complex (StreptABComplex/ 
HRP, Dako A/S) were then applied according to the 
manufacturer’s instructions. For UEA1 staining, we used a 
biotinylated UEA1 (Vector Laboratories) and a peroxidase- 
conjugated streptavidin-biotin complex (StreptABComplex/ 
HRP, Dako A/S). The peroxidase was localized by the diami­
nobenzidine-hydrogen peroxide reaction, and the sections 
were lightly counterstained with hematoxylin.
Endothelial Cell Cultures
HUVECs
HUVECs isolated by collagenase digestion were provided by 
Dr N. Maggiano (University of Rome, Italy) and were cultured 
in gelatin (1.5% )-coated tissue culture dishes or flasks (Falcon
Labware, Bccton-Dickinson) in medium 199 (GIBCO BRL, 
Life Technologies) supplemented with 20% fetal calf serum 
(GIBCO BRL), 4 mmol/L L-glutamine, 30 ¿¿g/mL endothelial 
cell growth supplement (Collaborative Research), 100 /xg/mL 
heparin (sodium salt, grade I, from porcine intestinal mucosa, 
Sigma Chemical Co), and antibiotics.
DMVECs
Normal DMVECs isolated from foreskin (Invitrocyte Inc) 
were grown in MEM (a  modification, GIBCO BRL) and 10% 
donor calf serum (GIBCO BRL).
PAGE-immunoblotting Analysis
Nonpathological heart and small intestine biopsies as well as 
cultured endothelial cell lines (HUVECs and DMVECs) were 
analyzed for E-FABP expression by PAGE-immunoblotting 
techniques under non denaturing conditions as described pre­
viously.10 Purified E-FABP8 was used as a standard. Rabbit 
antiserum against human E-FABP was used to detect
E-FABP.8 Similar experiments were performed using antisera 
directed against H-FABP and L-FABP.11
Cloning of E-FABP From Human Endothelial Cells 
RNA Isolation and cDNA Synthesis
Total cellular RNA from HUVECs and DMVECs was 
isolated according to the method of Chomczynsky and Sacchi.12 
PolyA+ mRNA was isolated from 2 jug total cellular RNA using 
a Dynabeads mRNA Direct kit (Dynal) according to the 
manufacturer’s instructions. First-strand cDNA synthesis was 
directly carried out on Dynabead-captured PolyA4 mRNA 
using 200 U  M-MLV reverse transcriptase purchased from 
GIBCO BRL and 0.5 mmol/L dNTPs from Pharmacia in a 
total volume of 20 ¡ j l L .
PCR
The cDNA mix was diluted 1:10, and 1 ¡ j l L  was used to 
perform a PCR. Since there is evidence that E-FABP is 
identical to the PA-FABP cloned by Madsen et al,13 the 
following primers based on the PA-FABP sequence were 
purchased from Amplimmun AG: sense primer (primer 1), 
5' -ATGGCCACAGTTCAGCAGCTG-31 (position 48 to 69 of 
the PA-FABP cDNA); anti-sense primer 1 (primer 2), 5'- 
CAGGTGACATTGTTCATGAC-3' (position 408 to 428 of 
the PA-FABP cDNA); and anti-sense primer 2 (primer 3), 
5'-TGCTCATTGAACTGAGCTTGG-3' (position 499 to 520 
of the PA-FABP cDNA). PCR was carried out in 20 mmol/L 
Tris-HCl, pH 8.4, 50 mmol/L KC1, 1.5 mmol/L MgCl2, 
0.2 mmol/L dNTPs each, and 0.25 /¿mol/L sense primer and 
anti-sense primer 1 or 2. After a denaturing step (3 minutes at 
94°C), 2.5 U  Taq polymerase from GIBCO BRL was added 
during a cooling step of 10 minutes at 80°C. Thirty-five PCR 
cycles were performed according to the following scheme:
1-minute denaturing at 95°C, 1-minute annealing at 50°C, and 
extension for L5 minutes at 72°C. After the last cycle, a final 
extension was performed at 72°C for 10 minutes.
Southern Blotting, Cloning, and Sequencing of 
PCR Products
The amplified cDNA fragments were separated in a 1,5% 
agarose gel and detected by ethidium bromide staining (0.5 
fjbg/mL). A  100-bp DNA ladder from GIBCO served as a 
molecular standard. Transfer of separated DNA onto a Hy- 
bond N filter (Amersham) and prehybridization were per­
formed as described previously.14 A  full-lengh PA-FABP cDNA 
was labeled using the Prime-a-Gene labeling kit from Promega 
according to the manufacturer’s instructions. Hybridization 
with the labeled cDNA probe was performed overnight at 65°G 
The filter was washed first at room temperature in 2X SSC/ 
0.1% SDS for 30 minutes and 0.5X SSC/0.1% SDS for 30 
minutes and then at 60QC in 0.1 X SSC/0.1% SDS for 30 
minutes and subsequently exposed to x-ray film. Cloning of the 
PCR products was done using the TA-cloning kit from Invitro- 
gen according to the manufacturer’s instructions. Plasmids 
were isolated, and inserts were subsequently sequenced using 
the T7 sequencing kit from Pharmacia.
Results
Immunolocalization of E-FABP in Human Tissues 
Controls
No staining was observed with preimmune serum in 
any of the tissue samples analyzed. A representative 
control experiment using placental tissue is shown in Fig 
1A. Cross-reactivity with intestinal FABP, L-FABP, and 
H-FABP types could be excluded, since these display 
specific tissue localizations that differ from that of 
E-FABP.41518 Comparative stainings with either fixation
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Fig 1. Localization of E-FABP in 
various human tissues as deter­
mined by immunohistochemistry. 
Paraffin-embedded sections from 
human tissues were stained using a 
rabbit anti-human E-FABP anti­
serum. No staining was observed 
with preimmune serum, as shown 
on a placental tissue section (A). 
When immune serum was used, 
E-FABP was strictly localized to en­
dothelial cells of the microvascula- 
ture in placental villi (B), skeletal 
muscle (C), heart (D), and ileal mu­
cosa (E). In panel F is a small venule 
in adipose tissue showing that in 
contrast to endothelial cells, peri­
cytes (arrows) were immunonega- 
tive. Umbilical artery (G) and vein (H) 
were negative. Bar=25 /xm.
method (10% formalin or Duboscq-Brazil solution) re­
vealed no significant differences.
Placenta at Term
Trophoblastic cells lining the placental villi were im- 
munonegative. The endothelium stained strongly for 
E-FABP in a high proportion of fetal microvessels, 
including capillaries and venules (estimated to be >85% 
of vascular cross sections) (Fig IB). Endothelium of 
small veins was occasionally positive.
Skeletal Muscle
Muscle cells from quadriceps did not express 
E-FABP. In contrast, the endothelial cells from the 
microvasculature surrounding the muscle fibers were 
clearly positive (Fig 1C).
Heart
No significant staining was observed in cardiomyo- 
cytes or endocardial endothelial cells, but the microvas- 
cular endothelium expressed E-FABP (Fig ID).
Small Intestine
The epithelium lining the intestinal crypts and villi was 
negative for E-FABP, whereas capillaries localized in 
these villi were strongly immunoreactive (Fig IE)» 
Venules identified in the mucosa were negative. The 
microvasculature was positive in the submucosa (not 
shown).
Adipose Tissue
In adipose tissue of the intestinal wall, heart, and 
hypodermis* capillaries surrounding adipocytes as well 
as small collecting venules (Fig IF) always exhibited 
intense immunostaining. On these paraffin-embedded 
sections, adipocytes did not demonstrate significant la­
beling (not shown).
Umbilical Cord
Umbilical cord vasculature consists of two arteries and 
a single vein that are devoid of vasa vasorum; E-FABP
300 Circulation Research Vol 81, No 3 September 1997
A
*
■
c
* y f ,V Â;
j *
t s
F '1' ' -  \ 
*  j
..r»
* * * -
$ ' *
ù f l : ■ U F % .
t
■ \
...1 V1 ’
*r
V
* •
•'/A .* #■'
B
I .v
#
>i.
T \ J ;
A •
• %. % -
g ^ .
*'• •Mi.
t ' Â  K v
X . ƒ ?
. i f  
A V ’
i \^V. * 
■i , • " ?
> »  i
»
i ?
5 . .
". r.
‘" « t e r - - - 1.•* *
WV»V
’ ï
%
\
:  à -  ,
>WSf
■ ^ ss^ ■«
4 %
• A
ri “N
J » '►s*
i i
i
* •• t
4 . .
>35?
' 4 ;
Vil
Tf, >■ . *  •
’  m r *  * m •'V*  * x  * 3 é ^ . * ¡i*
r
rjt
ax; '•
• •
v > \  ■■ - r ' . s i
- ,  -  4  v /  • • .  • •
y .*Y -%-^VV; ■ .-, •
ê » -sfc ♦' , <l W!>
«-■ »  ' ' '•*’ . j T l  •' ....... & t  ;.i.‘
,  ■ , . . . ,  f,t-■..•*111^
:^ .W  • * • :  •..•:,«•*• !' 
w - î - î^  • ' ’w
y • /t. /•' v •  ^ .■ -■ -  a i l  7 ■■..
v, .
. •.
\
Ü •
-F
.s '«'•
f- :.
n
4 1 ^  . #••■ . •*
■■. . f r r T -  ■ *  -V-' i '  , i
• i ! " ,: ^  : 
• , . , 'i iV  ...■•'•
I -n .î , . ,  ::r-:J
«• ^
'■ S . ÿ  •“
vi-
. -  * v  r ^ - M Z m - ,
- . m M . "  V . f
i *s
V
• >• T
€ ^ " »9
■■ SI,, : ;^t # :  ■■'■.: , » ^ v ,  ’S^, *t,:--:^ ; p ; ."::%*■■■> W ' ^ - '  y-\  ‘V .  .:^-., *
' 4>.r-#îPk: • ..Ji:-'. ,. . .  tk  ^  i™ *}-. - .* ' . . ' - ,  * .
. r«.. y  . >i . . \. . . f-'-Jr s '.j= t
•• .. . •• • ••
,,,S' . ¡VJ' : -.1'
N' ^ — *ip~rfÀiT*~»
V :  ' -  • ' *  , , ' T ' ' "XV
• i \  ' h  ^ • - ,%. .' ' î  . :>''':S''s  ' ,  . ' ■ *
r t i f  
. ..>ÎIT>". *% :«
Fig 2. Jmmunostamings forE- 
FABP and UEA1 on serial sections 
of the kidney. Endothelial cells in 
cortical vasculature were negative 
for E-FABP, including peritubular 
capillaries, glomeruli (arrow), and 
artery (star) (A); inthe medulla, the 
endothelium was E-FABP positive 
in the majority of peritubular capil­
laries but was negative in vasa 
recta (arrows) (B). In contrast, all 
endothelial cells were positive for 
UEA1 both in cortex (C; star indi­
cates artery; arrow, glomerule) and 
medulla (D; arrows indicate vasa 
recta). Scale bar=25 /xm.
was not detected in the endothelium of any of the 
umbilical vessels (Fig 1G and lH),The amniotic epithe­
lium lining the umbilical cord expressed E-FABP (not 
shown).
Smooth Muscle
Smooth muscle cells in the intestinal wall and in blood 
vessels (Fig 1G and 1H) were immunonegative.
Liver
No significant reactivity was detected in liver (not 
shown).
Kidney
The renal excretory system was immunonegative. In 
the cortex, the great majority of the vessels, including
glomeruli and their afferent and efferent arterioles, were 
not stained (Fig 2A); only rare capillaries were faintly 
positive (estimated at <5% compared with UEA1 stain­
ing). In the medulla, E-FABP was detected in the 
endothelium of a subpopulation of peritubular capillar­
ies (estimated at 80% compared with UEA1 staining), 
Vasa recta were negative (Fig 2B).
Lung
In bronchial epithelium, ciliated cells were immuno­
negative, whereas goblet cells expressed E-FABP (Fig 
3A), E-FABP was also detected in a subpopulation of 
alveolar epithelial cells, most probably type 2 pneumo­
cytes (Fig 3B). The peribronchial microvasculature was 
positive, and the alveolar capillaiy network was partially
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Fig 3. Localization of E-FABP in 
human iung. Gobiet cells in bron­
chial epithelium (A) stained strongly 
for E-FABP. A subpopulation of 
pneumocytes (B) were also positive 
(arrows), and the capillary alveolar 
network was partially labeled (ar­
rowheads) (B). Clara cells in termi­
nal bronchioles (C) were also posi­
tive; panel D is a higher 
magnification of the boxed area in 
panel C. Note the absence of stain­
ing of the large vessel (arrow) in 
panel C. Bar=25 ju,m.
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Comparative Study of E-FABP, vWF, and UEA1 in Endothelial Cells of Various Tissues
Arteries Capillaries Venules Veins
E-FABP vWF UEA1 E-FABP vWF UËA1 E-FABP vWF UEA1 E-FABP vWF UEA1
Placenta*! — + ~h + /- + /— + /- + /- + /- + /— + +
Heartf + + + + + + + — + +
Quadriceps — + + /- + + + + + — + + /-
Lung + + +/— + +/~ — + +
Ileal mucosa 4- +A- — — + —
Kidneyi
Cortex + + — + /- — + /- + — + +
Medulla + + +•/— — + — + /— + — + +
+ /~  indicates partially positive.
*The percentage of microvessels positive for E-FABP, vWF, and UEA1 was 85%, 75%, and 40%, respectively (estimated by vascular cross sections). 
tSmall veins occasionally stained.
^More than 95% of the cortical microvasculature, including glomeruli, was negative for E-FABP. In renal medulla, 80% of the peritubular capillaries were 
positive for E-FABP (compared with UEA1 staining).
stained (Fig 3B). Clara cells in terminal bronchioles 
were also labeled (Fig 3C and 3D).
Comparative Stainings of E-FABP, vWF, and UEA1 
in Various Organs
vWF and UEA1 were used to stain endothelial cells in 
order to compare their distribution with E-FABP. These 
data, summarized in the Table, revealed that E-FABP, 
vWF, and UEA'l had distinct expression patterns in 
endothelial cells from different tissues.
Depending on the organ studied as well as the local­
ization of the vasculature in each organ, a variable 
number of capillaries and venules were strongly E-FABP 
positive. Although small arterioles were relatively diffi­
cult to identify on routine histological sections, E-FABP 
was not detected in this compartment of the microvas­
culature. Pericytes did not express E-FABP (Fig IF).
As a general rule, in all organs studied, E-FABP was 
not detected in large blood vessels, including arteries, 
arterioles with internal elastic lamina, and large veins. 
Endothelial cells of small veins were only occasionally 
stained.
A  representative experiment comparing E-FABP and 
UEA1 expression in kidney vasculature is illustrated in
Fig 2.
Expression of E-FABP in Human Endothelial Cells
When protein extracts from intestine (Fig 4A, lanes 1 
and 2), heart (lanes 3 and 4), HUVECs (lanes 5 and 6), 
and DMVECs (lanes 9 and 10) (20 fig and 40 jag loaded 
for each sample) were analyzed by PAGE-immunoblot- 
ting with antiserum directed against E-FABP, the immu- 
noreactive band detected in these samples showed an 
electrophoretic mobility identical to purified E-FABP 
(lane 7 [0.5 ¡¿g] and lane 8 [0.01 /xg]), suggesting that 
E-FABP from the various tissues and cell lines is similar 
to E-FABP from keratinocytes. By comparing the inten­
sity of the purified E-FABP bands with bands from other 
samples, it was estimated that the amount of E-FABP 
per total protein ranges between 0.5% and 2%. Exper­
iments similar to those in Fig 4A were performed but 
with antisera against H-FABP (Fig 4B) and L-FABP 
(Fig 4C). Immunoreactive bands of H-FABP and 
L-FABP were detected in heart and intestine samples, 
respectively, whereas these FABPs could not be de­
tected in HUVECs and DMVECs. Moreover, no cross­
reactivity with E-FABP was observed.
Cloning of E-FABP From Human Endothelial Cells
In order to determine whether E-FABP transcripts 
are also expressed in human endothelial cells (HUVECs 
and DMVECs), we performed RT-PCR analysis using 
primers based on the sequence that has recently been 
published for PA-FAB P.™ Separation of the RT-PCR 
products by agarose gel electrophoresis and ethidium 
bromide staining revealed cDNA fragments of the ex­
pected sizes (a 380-bp fragment for reaction 1 and a 
472-bp fragment for reactions 2 and 3; see Fig 5A). 
Southern blotting using the radiolabeled PA-FABP full- 
length cDNA as a probe further confirmed the expres­
sion of E-FABP in endothelial cells (Fig 5B). In addition, 
the RT-PCR products were cloned, and both strands of
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Fig 4. Analysis of E-FABP in tissues, HUVECs, and DMVECs. 
PAGE-immunoblotting with antisera to E-FABP (A), H-FABP (B), 
and L-FABP (C) was performed on tissue extracts from intestine 
(lanes 1 and 2), heart (lanes 3 and 4), HUVECs (lanes 5 and 6), 
and DMVECs (ianes 9 and 10) (20 and 40 ¡jlg protein loaded for 
each tissue per cell line). The levels of E-FABP in the various 
samples were compared with purified E-FABP (lane 7 (0.5 mg] 
and lane 8 [0.01 mg]).
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Fig 5. Detection of RT-PCR products. RT-PCR products that 
were obtained using either primer 1 and primer 2 (reaction 1, lane 
1) or primer 1 and primer 3 (reaction 2, lanes 2 and 3) were 
separated in a 1.5% agarose gel and subsequently stained with 
ethidium bromide (A). The separated RT-PCR products were 
transferred onto a Hybond N filter and hybridized with radiola­
beled PA-FABP cDNA (B). Left margin shows molecular mass 
markers in base pairs. M indicates molecular mass marker; R1, 
RT-PCR product from reaction 1; R2, RT-PCR product from 
reaction 2; and HUVEC and DMVEC, the source of mRNA used 
for RT-PCR.
the cDNA were sequenced, revealing that the E-FABP 
and endothelial FABP are identical (data not shown).
Discussion
By immunohistochemistry, we have demonstrated that 
endothelial cells account for the immun ore active band 
similar to E-FABP, previously detected in human heart, 
intestine, and adipose tissue by PAGE-immunoblotting 
analysis.7’8 By cloning and sequencing of an E-FABP 
cDNA from cultured human endothelial cells (HUVECs 
and DMVECs), we have demonstrated that endothelial 
E-FABP is identical to keratinocyte E-FABP.13
FABPs are generally abundant in tissues, ranging 
between 0.1% and 6% of total protein.1'3 We previously 
reported that E-FABP is an exception, since its levels, as 
measured by binding capacity, were low in normal 
human tissues compared with other tissue FABPs. Using 
PAGE-immunoblotting analysis, we have shown that 
E-FABP is expressed at relatively high levels, ranging 
from 0.5% to 2%  of total protein in tissues, HUVECs, 
and DMVECs. The discrepancy between the values of 
these two measurements could be explained by post- 
translational modifications of E-FABP, which lower the 
affinity for tritiated oleic acid used as a tracer.8
We found that HUVECs express significant amounts 
of E-FABP, whereas the endothelium of umbilical vein, 
from which HUVECs are isolated, was negative by 
immunohistochemistry. Therefore, when endothelial 
cells are isolated from tissues and are subsequently 
cultured, they are likely to modify their ability to express 
E-FABP. Similar observations have been reported with
H-FABP, and this may in part explain the controversy 
concerning the presence or the absence of FABPs in 
endothelial cells: several immuno his to logical studies 
have demonstrated that H-FABP is widely distributed in 
microvascular endothelial cells from various mammalian 
tissues15'17^22; however, the amounts of H-FABP in en­
dothelial cells isolated from human umbilical artery,11 
rat heart,11*21’22 and bovine aorta23 have shown consider­
able variations, and in the present study, we did not find 
H-FABP expression in any of our endothelial cultures. 
Linssen et al22 reported a discrepancy between high FA 
oxidation by isolated cardiac endothelial cells and their 
low content of H-FABP; they hypothesized that two 
FABP types have to be present in the heart (one 
localized in cardiomyocytes and a second in endothelial 
cells) or that during culturing, endothelial cells might 
lose their capacity to express H-FABP. However, the 
presence of E-FABP in cultured DMVECs was in 
accordance with its immunodetection in the dermal 
microvasculature on skin sections (authors5 unpublished 
data, 1996). On the other hand, E-FABP could not be 
detected in transformed endothelial cells (HMEC-1), 
suggesting that this phenotype is lost during the trans­
formation process (data not shown). We hypothesized 
that FABP expression in isolated endothelial cells might 
be conditioned by the tissue of origin and by environ­
mental factors such as culture conditions. These data 
further indicate that conclusions about the in vivo con­
tent of FABPs in endothelial cells and about their 
putative functions should not be extrapolated exclusively 
from studies in vitro.
The lung was the only organ in which cell types other 
than endothelial cells and keratinocytes revealed 
E-FABP staining. Further biochemical investigation will 
allow us to determine whether this staining is due to the 
expression of E-FABP. The strongly stained Clara cells, 
goblet cells, and probably pneumocytes are implicated in 
the secretion of surfactant, muccopolysaccharides, and 
other components of lung fluid, respectively. Whether 
E-FABP might play a role in the secretory functions of 
these endoderm-derived cells remains to be elucidated.
The present study has shown that endothelial E-FABP 
is restricted to the microvasculature of various tissues, 
whereas larger blood vessels with muscular walls are 
usually immunonegative. Furthermore, not all capillar­
ies contained E-FABP, as shown by the absence of 
staining in liver and kidney cortex. The heterogeneity of 
endothelial cells is now well established: small-vessel 
endothelial cells are phenotypically, biochemically, and 
functionally different from large-vessel endothelial cells. 
Variations concerning specific in vivo functions also exist 
between endothelial cells derived from different or­
gans.24 Our results indicate that E-FABP expression in 
endothelial cells is related to the size of the vessels and 
to the nature of the tissue surrounding the endothelial 
cells. They indirectly suggest that E-FABP-mediated FA 
metabolism and/or transport occurs at the level of the 
micro vasculature in several target organs and that 
E-FABP expression might also be regulated by processes 
implicated in cell differentiation.
Microvascular endothelial cells play a central role in 
the delivery of nutrients such as FA to tissues. It is 
generally assumed that FAs are transported from the 
blood compartment to the interstitium directly through 
the cytoplasm of endothelial cells. Several mechanisms
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probably contribute to FA transfer across the vascular 
barrier, but they remain poorly understood21; the in­
volvement of endothelial H-FABP has been hypothe­
sized,19 but this remains controversial.21 Interestingly, 
E-FABP is strongly expressed in capillary endothelial 
cells of several tissues that participate actively in the 
metabolism of FA, in locations where an important 
traffic of free FA occurs from the blood compartment to 
tissue cells (and/or vice versa): around adipocytes, serv­
ing as lipid storage cells and as a readily available source 
o f  energy; in the small intestine, where intestinal FAs are 
absorbed; and in the microvasculature of heart and 
skeletal muscles, which require high levels of blood- 
derived FA for energy. It is noteworthy that a complex 
pattern of FA metabolism and transport also occurs 
in  the placenta,25 which contains several FABP 
types.11*15-18’26 This organ has a high FA requirement for 
its own energy and structural needs and for supplying 
FAs to the fetus. Since fetal capillaries from placental 
villi strongly express E-FABP, this protein may be 
important for the transfer of free FAs from maternal 
blood to the fetus. Our data support the idea that 
E-FABP is involved in the uptake and transport of free 
FAs across the endothelial cytoplasm. The presence of 
E-FABP in endothelial cells of the microvasculature 
might also suggest that these cells must undergo FA- 
mediated activation to perform their functions of uptake 
and release of various metabolites.
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